Statement re. Press Comment

RNS Number:5725H
Oxford Glycosciences PLC
17 February 2003

Not for release, publication or distribution in, into or from Australia, Canada
or Japan


17th February, 2003


                        Oxford GlycoSciences plc ("OGS")


OGS confirms that a number of parties, including Celltech Group plc, have
requested information concerning OGS under Rule 20.2 of The City Code on
Takeovers and Mergers.  OGS has not received any proposal regarding a potential
offer other than from Cambridge Antibody Technology Group plc.


Enquiries:


Oxford GlycoSciences
David Ebsworth, Chief Executive Officer              [phone]
Denis Mulhall, Chief Financial Officer


Goldman Sachs International
Michael Hill                                         [phone]
Basil Geoghegan


Financial Dynamics (UK)
Tim Spratt                                           [phone]
Melanie Toyne-Sewell


Financial Dynamics (US)
Leslie Wolf Creutzfeldt                              [phone]
Deborah Arden Jones


Goldman Sachs International is acting for OGS and for no-one else in connection
with this announcement and will not be responsible to any other person for
providing the protections afforded to clients of Goldman Sachs International or
for providing advice in relation to the Offer or the contents of this
announcement.


This announcement does not constitute an offer to sell or invitation to purchase
any securities or the solicitation of any vote or approval in any jurisdiction.


The release, publication or distribution of this announcement in certain
jurisdictions may be restricted by law and therefore persons in such
jurisdictions into which this announcement is released, published or distributed
should inform themselves about and observe such restrictions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

SPCMGGMZZNMGFZM